KeyBanc lowers UnitedHealth stock price target to $400 from $450

KeyBanc lowered its price target on UnitedHealth Group (UNH) to $400 from $450, maintaining an Overweight rating, citing a potentially overly pessimistic valuation given its 12.5x P/E ratio and strong fundamentals (EBITDA of $36.2B). Despite near-term uncertainties and the resignation of board member Andrew Witty, other firms like JPMorgan (PT $405), Wolfe Research (PT $390), and Bernstein SocGen Group (PT $377) also maintain Outperform ratings, emphasizing OptumHealth's performance and the likelihood of margin improvements beyond 2025, suggesting a possible long-term undervaluation.

Analysis

KeyBanc has revised its price target for UnitedHealth Group (UNH) to $400 from $450, while reiterating an Overweight rating, suggesting the current valuation at a 12.5x P/E ratio is overly pessimistic, particularly concerning Medicare Advantage (MA) business margins. This view is supported by InvestingPro data indicating the stock is in oversold territory despite robust fundamentals, including a last-twelve-months EBITDA of $36.2 billion. Analysts anticipate that challenges impacting 2025 performance are likely to be transitory, with resolution expected from 2026 onwards, implying the current historically discounted valuation due to depressed margins may not persist. UnitedHealth's financial strength is further underscored by a 33-year history of consistent dividend payments and a strong free cash flow yield. This optimistic long-term outlook is echoed by other firms: JPMorgan (Overweight, $405 PT), Wolfe Research (Outperform, $390 PT), and Bernstein SocGen Group (Outperform, $377 PT) all maintain positive ratings, highlighting the critical role of OptumHealth's performance and expecting eventual margin improvements, even after the company withdrew its 2025 guidance. The recent resignation of Andrew Witty from the board of directors represents a governance change ahead of the annual shareholder meeting. Amidst an industry backdrop of rising employee healthcare costs, as noted by UBS, the consensus among analysts points towards UNH being undervalued relative to its long-term earnings potential, although InvestingPro's AI-driven analysis did not rank UNH at the top of its list for stocks with massive upside.

Key Decisions for Investors

• Investors might consider the current valuation as a potentially attractive entry point for long-term exposure, given the consensus analyst view that near-term margin pressures are temporary and UNH's strong fundamentals and dividend history.
• Closely monitor developments in Medicare Advantage margins, the performance of OptumHealth, and any further clarity regarding the 2025 outlook, as these are key catalysts for potential re-rating.
• While analyst sentiment is largely positive, the recent board member resignation and the observation that InvestingPro's AI did not highlight UNH as a top hidden gem warrant a balanced approach, suggesting continued due diligence on relative value and specific risk factors.